BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22111227)

  • 1. [Osteoporosis in castration therapy--a neglected field].
    Bratt O; Akesson K
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
    [No Abstract]   [Full Text] [Related]  

  • 2. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
    Briot K; Paccou J; Beuzeboc P; Bonneterre J; Bouvard B; Confavreux CB; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Lespessailles E; Mayeur D; Mongiat Artus P; Vieillard MH; Debiais F
    Joint Bone Spine; 2019 Jan; 86(1):21-28. PubMed ID: 30287350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer].
    Eiken PA; Langdahl BL; Eiken FL; Walter S; Poulsen MH; Abrahamsen B
    Ugeskr Laeger; 2011 Nov; 173(48):3093-6. PubMed ID: 22118650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of fracture after androgen deprivation for prostate cancer.
    Walsh PC
    J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
    Taxel P; Dowsett R; Richter L; Fall P; Klepinger A; Albertsen P
    BJU Int; 2010 Nov; 106(10):1473-6. PubMed ID: 20456336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metastases and bone loss medical treatment in prostate cancer patients.
    Safriadi F
    Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW; Dunn SR; Ferguson DW; Lomas G; Niazi Z; Stratte PT
    J Urol; 2000 Jan; 163(1):181-6. PubMed ID: 10604342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Diethylstilbesterol revisited: androgen deprivation, osteoporosis an prostate cancer.
    Pitts WR
    J Urol; 2002 Jul; 168(1):201; author reply 201. PubMed ID: 12050534
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevent and manage bone loss in men receiving androgen deprivation therapy.
    Becze E
    ONS Connect; 2010 Apr; 25(4):18-9. PubMed ID: 20437748
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteoporosis after orchiectomy for prostate cancer.
    Daniell HW
    J Urol; 1997 Feb; 157(2):439-44. PubMed ID: 8996327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we doing enough to promote bone health in men with prostate cancer?
    Boyd LA
    Urol Nurs; 2008 Dec; 28(6):412-3. PubMed ID: 19241777
    [No Abstract]   [Full Text] [Related]  

  • 20. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.